Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$176.6m

Capricor Therapeutics Past Earnings Performance

Past criteria checks 0/6

Capricor Therapeutics's earnings have been declining at an average annual rate of -23.5%, while the Biotechs industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 77.3% per year.

Key information

-23.5%

Earnings growth rate

29.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate77.3%
Return on equity-131.9%
Net Margin-89.7%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

Revenue & Expenses Breakdown

How Capricor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CAPR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2427-24130
31 Dec 2325-22130
30 Sep 2314-29121
30 Jun 239-29120
31 Mar 236-29110
31 Dec 223-29100
30 Sep 222-27101
30 Jun 220-2590
31 Mar 220-2380
31 Dec 210-2080
30 Sep 210-1870
30 Jun 210-1860
31 Mar 210-1760
31 Dec 200-1460
30 Sep 200-1150
30 Jun 201-950
31 Mar 201-740
31 Dec 191-840
30 Sep 191-940
30 Jun 192-1240
31 Mar 192-1450
31 Dec 182-1550
30 Sep 181050
30 Jun 182250
31 Mar 182250
31 Dec 173250
30 Sep 173-1450
30 Jun 174-1750
31 Mar 174-1850
31 Dec 164-1950
30 Sep 164-1850
30 Jun 165-1550
31 Mar 165-1440
31 Dec 156-1340
30 Sep 156-1140
30 Jun 156-1040
31 Mar 156-840
31 Dec 145-630
30 Sep 143-930
30 Jun 142-930
31 Mar 141-930
31 Dec 131-920
30 Sep 131-520
30 Jun 132-420

Quality Earnings: CAPR is currently unprofitable.

Growing Profit Margin: CAPR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CAPR is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.

Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: CAPR has a negative Return on Equity (-131.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.